Exciting news for Australian families: the cost of life-changing medications is about to drop dramatically! But here's where it gets even better—starting in 2026, several groundbreaking treatments will be more accessible than ever through the Pharmaceutical Benefits Scheme (PBS). Among these is the expanded use of adalimumab (brand name Humira), now approved to tackle juvenile idiopathic arthritis in addition to its existing uses for conditions like Crohn’s disease, ulcerative colitis, and chronic plaque psoriasis. This drug works by soothing an overactive immune system, reducing inflammation, and offering hope to the estimated 30,100 young Australians battling arthritis. Thanks to the PBS subsidy, the cost per prescription plummets from a staggering $650 to just $25—a game-changer for families. And this is the part most people miss: this isn’t the only medication getting a spotlight. Odevixibat (Bylvay) is making its PBS debut as a treatment for progressive familial intrahepatic cholestasis, a rare genetic liver disease primarily affecting children. Meanwhile, ublituximab (Briumvi) is also joining the list as a first-time treatment for relapsing-remitting multiple sclerosis (RRMS). This medication targets B-cells to curb inflammation, reduce relapses, and slow disease progression—a lifeline for the over 14,000 patients who relied on similar treatments in 2024, previously facing costs of around $15,000 per script without subsidy. But here’s the controversial part: Is this enough? While the reduction in PBS co-payments from $31.60 to $25 (effective January 1, 2026) is a step forward, the concessional co-payment remains at $7.70 until 2030. Is this fair for those on concessional rates? And with RRMS treatments like ocrelizumab (Ocrevus) already listed in December, are we doing enough to support patients with chronic conditions? These changes are undoubtedly positive, but they also spark important questions about equity and accessibility in healthcare. What do you think? Are these updates a win, or is there more work to be done? Share your thoughts below—let’s keep the conversation going!
